ResMed's (NYSE:RMD) stock up by 3.2% over the past month. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. Particularly, we will be ...

Another blue chip ASX share I would happily build a portfolio around is REA Group. Its property platforms sit at the centre ...

The market expects Sherwin-Williams (SHW) to deliver a year-over-year increase in earnings on higher revenues when it reports ...

ResMed (NYSE:RMD) supports global respiratory care as s&p 500 chart discussions frame large healthcare organizations.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

ResMed CEO Mick Farrell has become the first leader from the home care sector to chair the board of directors at AdvaMed, the trade association representing major medtech companies.

The projected fair value for ResMed is US$258 based on 2 Stage Free Cash Flow to Equity ResMed's US$258 share price indicates ...

Canaday was named chief of staff for the executive team at Resmed in January 2022. Later that year, she moved into the ...

If you are wondering whether ResMed's current share price still offers value, this article walks through what the numbers are ...

These shares have smashed the market and look well-placed to continue this trend. The post 3 unstoppable ASX 200 shares to buy and hold forever appeared first on The Motley Fool Australia.

With Q3 behind us, let’s have a look at ResMed (NYSE:RMD) and its peers. Patient monitoring companies within the healthcare ...

RMD is seeing rising device demand, expanding international sales and strong liquidity, but macroeconomic pressures could ...